Clinical Trial Update: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating circulating tumor DNA as a predictive marker to guide an early treatment switch in metastatic breast cancer; status is not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: University of Miami | Conditions: Breast Cancer, ER-positive Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING